Wanbury Ltd, country’s fastest growing pharmaceutical company as per the latest ORG IMS, has launched an advanced form of its anti-anaemia drug Cpink (Ferrous Ascorbate). The product is called Cpink IIC and will be used in the treatment of anaemia in pregnant women and children.

Cpink IIC has been introduced with a unique Integrated Iron Complexation Technology, resulting in a significant reduction in the gastro-intestinal (GI) irritation and can result in increased absorption of iron in the body, compared to the existing ferrous ascorbate brands in the country.

Cpink is currently the second largest selling brand in iron segment with a turnover of Rs 30 crore and with a 19 per cent market share as per the latest ORG IMS data. With the new technology, Wanbury expects to revolutionize the Iron and ferrous ascorbate market. Led by a product with high patient compliance and significant clinical haemoglobin rise, Wanbury expects to reach the number one position in the ferrous ascorbate market.

Indian market for haematinic products is at around Rs 900 crore, which is growing at 13 per cent annually. Of this, the ferrous ascorbate market is around Rs 190 crore and growing at 35 per cent.

Dr. Rajaram Samant, executive director and the head of the formulations business, Wanbury, said, “India is the anaemia capital of the world as patients do not continue the medication on account of high incidence of GI irritations in the existing ferrous ascorbate brands. The IIC technology developed by the company reduces the GI irritations by 30 per cent, inducing the patients to continue the medication for the prescribed period of 6-8 months thereby eradicating anaemia to a very large extent.”

“The IIC technology utilizes optimum ratio of iron and ascorbic acid- the only complexation ratio approved by US EAFUS (Everything Added to Food in US) body. The result is the most stable ferrous ascorbate complex which minimizes GI irritations and can maximize iron absorption. This will lead to better patient compliance and better haemoglobin rise. The first Indian clinical trial has confirmed that with this technology there is a 30 per cent reduction in gastrointestinal adverse effects as compared to other top ferrous ascorbate brand,” said Dr. Pramod Dhembare, the principal investigator in the clinical trial conducted at an US FDA approved Clinical Research Organisation.